Literature DB >> 17229052

Characterization of endothelial-like cells derived from human mesenchymal stem cells.

J W Liu1, S Dunoyer-Geindre, V Serre-Beinier, G Mai, J-F Lambert, R J Fish, G Pernod, L Buehler, H Bounameaux, E K O Kruithof.   

Abstract

BACKGROUND: Blood-derived endothelial progenitor cells (EPC) have been used to treat ischemic disease. However, the number of EPC that can be obtained from adult blood is limited.
OBJECTIVE: To characterize endothelial-like cells obtained from human bone marrow and determine their ability to stimulate new blood vessel formation in vivo.
METHODS: Mononuclear cells (MNC) were isolated from human bone marrow or umbilical cord blood and cultured in endothelial growth medium (EGM-2). Mesenchymal stem cells (MSC) were isolated from bone marrow and induced to differentiate into endothelial-like cells (MSCE), or adipocytes or osteocytes by growth in EGM-2, adipogenic or osteogenic medium.
RESULTS: Cells obtained by culturing bone marrow MNC in EGM-2 formed cord- or tube-like structures when grown on Matrigel(TM) and expressed several endothelial marker proteins. However, cell morphology and the profile of endothelial marker protein expression were different from those of cord blood-derived EPC (cbEPC). Cells with a similar phenotype were obtained by differentiation of MSC into MSCE, which was accompanied by an increase of endothelial marker proteins and a diminished capacity to differentiate into adipocytes. Subcutaneous implantation of MSCE in collagen plugs in non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice resulted in formation of functional blood vessels that had incorporated the MSCE.
CONCLUSIONS: Our results show that MSCE and cbEPC are different cell types. The formation of functional blood vessels by MSCE, combined with high yields and a reduced capacity to differentiate into other cell types compared with MSC, makes these cells potentially useful for autologous therapy of ischemic disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229052     DOI: 10.1111/j.1538-7836.2007.02381.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  36 in total

1.  Toward an in vitro vasculature: differentiation of mesenchymal stromal cells within an endothelial cell-seeded modular construct in a microfluidic flow chamber.

Authors:  Omar F Khan; M Dean Chamberlain; Michael V Sefton
Journal:  Tissue Eng Part A       Date:  2011-12-02       Impact factor: 3.845

Review 2.  Monitoring of endothelial dysfunction in critically ill patients: the role of endothelial progenitor cells.

Authors:  Sushma K Cribbs; Greg S Martin; Mauricio Rojas
Journal:  Curr Opin Crit Care       Date:  2008-06       Impact factor: 3.687

3.  Comparative characteristics of endothelial-like cells derived from human adipose mesenchymal stem cells and umbilical cord blood-derived endothelial cells.

Authors:  Taghrid M Gaafar; Hala A Abdel Rahman; Wael Attia; Hala S Hamza; Konrad Brockmeier; Rabab E El Hawary
Journal:  Clin Exp Med       Date:  2013-05-07       Impact factor: 3.984

Review 4.  Mesenchymal stem cells: Potential role in corneal wound repair and transplantation.

Authors:  Fei Li; Shao-Zhen Zhao
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

5.  Differentiation of umbilical cord lining membrane-derived mesenchymal stem cells into endothelial-like cells.

Authors:  Chinh Chung Doan; Thanh Long Le; Nghia Son Hoang; Ngoc Trung Doan; Van Dong Le; Minh Si Do
Journal:  Iran Biomed J       Date:  2014

6.  Long term culture and differentiation of endothelial progenitor like cells from rat adipose derived stem cells.

Authors:  Monire Amerion; Mojtaba Rezazadeh Valojerdi; Saeid Abroun; Mehdi Totonchi
Journal:  Cytotechnology       Date:  2017-12-20       Impact factor: 2.058

7.  The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents.

Authors:  Umberto Galderisi; Antonio Giordano; Marco G Paggi
Journal:  World J Stem Cells       Date:  2010-02-26       Impact factor: 5.326

Review 8.  Is CD34 truly a negative marker for mesenchymal stromal cells?

Authors:  Ching-Shwun Lin; Hongxiu Ning; Guiting Lin; Tom F Lue
Journal:  Cytotherapy       Date:  2012-11       Impact factor: 5.414

9.  In Situ Crosslinkable Gelatin Hydrogels for Vasculogenic Induction and Delivery of Mesenchymal Stem Cells.

Authors:  Sue Hyun Lee; Yunki Lee; Young Wook Chun; Spencer W Crowder; Pampee P Young; Ki Dong Park; Hak-Joon Sung
Journal:  Adv Funct Mater       Date:  2014-11-19       Impact factor: 18.808

Review 10.  Amniotic fluid-derived stem cells for cardiovascular tissue engineering applications.

Authors:  Jennifer Petsche Connell; Gulden Camci-Unal; Ali Khademhosseini; Jeffrey G Jacot
Journal:  Tissue Eng Part B Rev       Date:  2013-03-14       Impact factor: 6.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.